Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
August 2023
in “
JAMA Dermatology
”
Studysummary In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on doi.org →